产品描述信息
NR-431??Vaccinia virus, Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-16), (produced in vitro) (Monoclonal Antibodies)|Vaccinia virus|Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-16), (produced in vitro) |-20°C or colder|GH Cohen, RJ EisenbergAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Vaccinia Virus (WR) B5R Protein, Residues 20 to 275 (Ectodomain), (similar to VMC-16), (produced in vitro), NR-431."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.Mouse monoclonal antibody to a recombinant form of the B5R envelope glycoprotein [B5R(275t); residues 20 to 275 comprising the ectodomain, N-terminal histidine-tagged] of the Western Reserve (WR) strain of vaccinia virus was purified from a mouse B cell hybridoma using ammonium sulfate precipitation and size exclusion chromatography. The mouse B cell hybridoma was generated by the fusion of SP2/0 myeloma cells with immunized BALB/c splenocytes. NR-431 was purified from the same hybridoma as VMC-16. The specificity of VMC-16 was determined by reactivity to B5R(275t) by ELISA and confirmed by Western blot analysis under reducing and non-reducing conditions. The reactivity pattern in ELISA assays using overlapping peptides spanning residues 20 to 275 of B5R indicates that VMC-16 recognizes epitopes within amino acids 56 to 75 and 254 to 264. VMC-16 does not neutralize the infectivity of the extracellular enveloped virus (EEV) form of vaccinia virus in BS-C-1 cells using an EEV plaque reduction assay. VMC-16 does not inhibit the comet tail formation of the EEV form of vaccinia virus in BS-C-1 cells using a comet tail inhibition assay.Each vial contains approximately 1.0 mL of purified monoclonal antibody in 50 mM borate buffer (pH 8.0 +/- 0.2) containing 0.1 M sodium chloride and no preservatives.